2020 China NASH Conference . . . Fifth round of notifications.

Introduction: To explore the tactics for the efficient development of new NASH drugs, NASH Conference should not be missed.
(Press and hold to identify the QR code and sign up now!) Organizers say non-alcoholic fatty hepatitis (NASH) is a major health problem affecting hundreds of millions of people around the world, and so far there are no specific drugs approved by mainstream regulators, so this is a huge unsettle clinical need.
years, many Chinese and foreign enterprises have joined the field of NASH, hoping to make a breakthrough.
, NASH's new drug research and development has been in the news over the past few months, from obecholic acid to GFT505.
the road to new drug development has never been easy, and we remain confident about the future of NASH - is winter coming and spring still far away? At this critical time, the China NASH New Drug Alliance and The Pharmaceutical Age will jointly hold China's first international conference focusing on NASH new drug research and development, the 2020 China NASH Congress, on September 24-25, 2020.
conference aims to report on the latest industry developments and explore strategies and tactics for the efficient development of new NASH drugs to restore morale and accelerate the development and launch of new NASH drugs, ultimately benefiting hundreds of millions of patients in China and around the world.
event has received strong support from leaders in clinical/drug research and development at home and abroad, and more than 30 experts from home and abroad have been identified to attend the presentation.
conference topics cover the most popular topics such as NASH molecular biology, cutting-edge clinical progress, new drug target development, and clinical trials.
China NASH New Drug Alliance, as a non-profit industry organization focusing on NASH new drug research and development, brings together institutions and individuals in research and development, medical, service, investment, supervision, consulting and other related industries, through sharing information, holding conferences, training and other activities to promote exchanges between members, industry colleagues, cooperation and interaction and cooperation between the alliance and regulatory agencies, similar organizations abroad, to enhance the overall level of research and development of new drugs in China, and ultimately promote and accelerate the development of new drugs in China, and ultimately accelerate the development of new drugs in China.
2020 Alliance's online and offline activities have been carried out, the Alliance will be 23 first member units on the basis of further expansion of scale and impact, for the industry and society to make their greatest contribution.
we warmly welcome our friends to attend! Looking forward to meeting with you in Shanghai to discuss NASH new drug research and development plan! How to register your meeting schedule (please select one of them) (i) Scan QR code (2) Please copy the link below and open it in your browser.
Hotel Information 1. Shanghai Da Wanli Hotel Details Address: Shanghai Pudong New Area Changliu Road 100 (near Yingchun Road) traffic advice: airport, train station taxi direct, or take the subway line 9, Yang High School Road Station after getting off the bus 15 minutes walk.
Drug Age Agreement Price: $800 Deluxe Room (including early) Reservations Deadline: August 28, 2020, real-time discounted rates after the deadline Room Reservations: 021-387148 88 to 6921Chancy, Chancy.Cai@renaissancehotels.com2. ibis Shanghai Union Hotel Address: 200 Fangdian Road, Pudong New Area, Shanghai, D-Floor Medicine Times Price: $350 inclusive Early) Contact: Pudong Tai 13585887142 Exhibiting Roadshow Related Matters Contact: Mr. Will Tel: 13564569657 WeChat: 276741 E-mail: will.wei@drugtimes.cn Business Cooperation: Ms. Wei Tel: 17811892253 WeChat: weina2253 E-mail: weina@drugtimes.cn Important Statement to ensure the smooth and successful holding of the event, To protect the safety and interests of all parties, please read the following in detail: 1, the schedule of this activity is constantly updated, please continue to pay attention to the pharmaceutical era on the public number of the event notice, and ultimately the actual situation on the spot.
2, if the event due to the host's problems can not be held as planned, the sponsor will refund the full amount of the registration fee, without any other costs and responsibilities.
. If the Force Maje force event cannot be held as planned, sponsor will only refund the registration fee (net of the 2% service charge of the third party registration platform) and will not be liable for any other costs and responsibilities.
4. If a friend who has purchased a ticket withdraws from the event or cancels registration, please inform the sponsor at least 2 days in advance that the sponsor will refund the registration fee (less the 2% service charge of the third party registration platform) and that the sponsor has the right to refuse the refund if the sponsor is notified less than 2 days later.
5. Any friend who registers to participate in the activities shall be regarded as a person with full civil capacity, such as any damage caused by the violation of laws and regulations or personal accidents in the event, and shall bear full responsibility by the participants, and the sponsor shall not bear any legal or economic responsibility.
6, the organizers have the right to use the photos taken during the event for publicity and promotion.
, once registered, is deemed to have been read and accepted.
8, the final interpretation of the event is owned by the organizer.
The epidemic prevention tips for the implementation of the "State Council to deal with the new coronavirus infection pneumonia epidemic joint prevention and control mechanism on the new coronary pneumonia epidemic normal prevention and control work guidance" (National Invention Electric Power (2020) No. 14) and other requirements, Organizers /hotels have developed epidemic prevention and control measures, I hope guests know, please see below: self-examination please determine the following information: 1, I have not been diagnosed with pneumonia confirmed cases or suspected cases; Contact; 3, I have not been in close contact with people from high-risk areas in the outbreak in the past 14 days; 4, I have not been to high-risk areas in the outbreak in the past 14 days; 5, I have not been left to the inspection station centralized isolation observation or observation After the lifting of medical observation; 6, I do not currently have fever, cough, fatigue, chest tightness and other symptoms; 7, before coming to Shanghai to actively query the risk level of the outbreak in the region, and in advance in the "Alipay" claim "with the application code" and the trajectory of action 14 days before the meeting (8 September - 22 September).
you can scan the QR code below to see your 14-day trajectory.
Venue inspection 1, before admission to the conference, the organizer/hotel will measure the temperature of each guest, if there is abnormal temperature, can be properly rested after the use of other equipment or other means to measure again, if still unqualified, the organizer/hotel has the right and obligation to report, and ask you to seek medical attention; You wear your brand name or check-in certificate throughout the meeting, 3, during the meeting is recommended to wear a mask, and maintain an appropriate distance, 4, guests encounter fever, dry cough and other physical discomfort must immediately report to the organizers / hotel staff and timely arrangements for isolation, 5, during the meeting, please pay attention to the situation of the epidemic and control measures changes.
2020 China NASH Conference sponsor Sino-American Crown Biotech Co., Ltd. Sino-American Crown Biotech Co., Ltd. (CrownBio) is a global drug discovery and development company, providing a platform for transforming medicine to advance research on tumor, inflammatory, cardiovascular and metabolic diseases.
we are committed to science-based, integrity first, to provide customers with excellent clinical candidates.
Sino-American Crown has the most comprehensive in vitro, in vivo and ionoid biopharmaceutical research and development outsourcing one-stop service, from traditional cell line to congener model, human tumor allogeneic transplantation (PDX) model, human tumor allogeneic transplant model source of tumor organs (PDXO) and human tumor organs (PDO) and has professional model development technology, comprehensive drug discovery platform and drug research and development capabilities around the world, which enable us to provide reliable pharmaceutical support for the rapid development of the pharmaceutical industry.
Pharmaceuticals Mingkangde Pharmaceuticals Mingkangde for the global biopharmaceutical industry to provide a full range of integrated new drug research and development and production services.
by empowering pharmaceutical, biotechnology and medical device companies around the world, Pharmaceuticals is committed to driving the development of new drugs and delivering breakthrough treatment solutions to patients.
In line with research as the first, customer-centric purposes, pharmaceutical Mingkang through cost-effective and efficient research and development services, to help customers improve research and development efficiency, services covering chemical drug research and development and production, cell and gene therapy research and development production, medical device testing and other fields.
At present, drug Mingkangde's enabling platform is carrying more than 3,900 partners from more than 30 countries around the world research and development innovation projects, is committed to bringing more new drugs, good drugs to patients around the world, as soon as possible to achieve the "no difficult medicine, difficult to cure the disease" vision.
Hangzhou Chip Technology Co., Ltd. Hangzhou Chip Technology Co., Ltd. is an independent research and development technology, aimed at providing technical services for pharmaceutical companies and research institutions.
parent company is Singapore-based medical technology company HistoIndex ®, founded in April 2010 as a spin-off of Singapore's largest scientific and technological research institute (A-STAR) and the Nanotechnology Research Institute (IBN).
is mainly engaged in the development, manufacture and sale of digital pathological imaging systems for non-dyed fibrosis, while providing corresponding technical services, dedicated to help pharmaceutical companies to carry out research and development analysis of new drugs, accelerate the market process.
we use the combination of artificial intelligence image analysis technology and globally original colorless imaging technology for the evaluation of disease progression, especially in the pathological evaluation of the development of new drugs in NASH.
At present, the technology platform has done in-depth research and algorithm verification in NASH preclinical animal models and multiple II, III clinical trials, and has participated in the completion of nearly 40 international and domestic well-known pharmaceutical companies, large CRO companies and scientific research institutions sponsored by the relevant trials.
technology can accurately analyze the early changes of fibrosis and provide a true, objective and reliable basis for the declaration and internal decision-making of new drugs in NASH drug research and development.
Biotech (Suzhou) Co., Ltd. Kaisai Biotech (Suzhou) Co., Ltd. (KCI) is a CRO company that provides preclinical errative and pharmaceutical evaluation technical services for pharmaceutical research and development.
is committed to establishing a comprehensive preclinical physiotherapy and pharmaceutical evaluation platform for small animals, providing professional preclinical pharmacological evaluation services in the fields of cardiovascular disease, immunological disease, inflammatory disease, metabolic disease, urinary system disease, neuropathy and tumor disease.
, we also conduct PK/PD, early non-GLP toxicology, medical imaging, translational medicine and pathology research services.
company is located in Suzhou Industrial Park Jinji Lake nano-city, office, experimental area of 1800m2, including large, mouse SPF-class barrier system 800m2, functional laboratory 600m2, can simultaneously carry out 7000 mice, 5000 rat pharmacology, pharmacological experiments.
has obtained the "Experimental Animal Use License" and international AALAC certification in Jiangsu Province.
Corinthic Biotech Co., Ltd. Kunming Colling Biotech Co., Ltd. (KBI) is the world's leading non-human primate pharmacological disease model and drug safety evaluation CRO company.
company has 200 employees (nearly 20 overseas executive teams) and AALAC certified animal breeding and experimental centers.
provides preclinical pharmacological and safety evaluations in the following areas: metabolic diseases (diabetes, obesity, lipid abnormalities, etc.); autoimmune and inflammatory diseases (rheumatoid arthritis, lupus nephritis, etc.); central nervous system diseases (Alzheimer's disease, Parkinson's disease, cognitive impairment, etc.); tumor immunity (T-cell regulation, cytokine storm regulation).
10 years of development, we have cooperated extensively with 18 of the world's top pharmaceutical companies and more than 200 biotechnology companies at home and abroad in the field of new drug research and development.
ResearchDiets, Inc. is committed to producing OpenSource® purified feed and providing professional research advice on experimental animal nutrition, and has long worked with leading global suppliers of experimental animals with related biotechnology companies such as Taconic Biosciences More than 25,000 unique laboratory animal feeds have been successfully developed, including The Jackson Laboratory, Charles River Laboratories and Gubra, with nearly 2,000 references to NASH-related literature alone.
ResearchDiets offers a range of purified feeds for inducing NAFLD disease models, such as high-fat feed, methionine choline deficiency (MCD) feed, choline deficiency amino acid (CDAA) feed, and improved AMLN feed (high-fat, high fructose high cholesterol).
addition to this, ResearchDiets has more feeds that can highly simulate clinical NASH characteristics.
The ResearchDiets Nutrition Science Team, made up of ten PhD-level technical support, combines decades of experience in the deployment of purified feed to provide you with literature on non-alcoholic fatty liver disease and explain the metabolic mechanisms and ideoplasms of animal models of dietaryly induced diseases.
Huayin Health Huayin Medical Research Institute, relying on Huayin Health Diversified and Standardized Testing Platform, focuses on clinical research and accompanying diagnostic business, providing customers with specialized technical services and solutions such as preclinical research, I-IV drug clinical research, large-scale multi-center research, data management and statistical analysis, to provide high-quality data for drug efficacy and safety evaluation.
as a central testing institution for professional services throughout the process of clinical trials of new drug research and development, Huayin Medical Research Institute is integrated into the international standardized quality management system and strictly follows the relevant laws and regulations of clinical trials.
the implementation of the whole process, all elements, the quality management of the entire staff, is committed to become the pharmaceutical products and manufacturers of the most professional, comprehensive one-stop regulations and technical support service providers and partners.
Huayin Health Laboratory Technology Center is headquartered in Guangzhou, in Guangzhou Science City Science and Technology Innovation Base has 2500m2 clinical testing and research laboratory, in the Southern Medical University Life Sciences Building has 2300m2 pathology diagnosis and molecular pathology center.
center subject set up comprehensive, perfect facilities, advanced equipment and equipment, in all fields are employed authoritative expert guidance.
innovation in Guangzhou Science City.